Levodopa/carbidopa extended-release - Impax Pharmaceuticals

Drug Profile

Levodopa/carbidopa extended-release - Impax Pharmaceuticals

Alternative Names: 587124; Carbidopa/levodopa extended-release capsules - IMPAX Laboratories; GSK-587124; IPX-066; NUMIENT; Patrome; Rytary

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Impax Pharmaceuticals
  • Class Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
  • Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Parkinson's disease

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 25 Nov 2015 Adverse events data from phase III clinical trials in Parkinson's disease released by Impax Laboratories
  • 25 Nov 2015 Registered for Parkinson's disease in European Union, Norway, Norway, Liechtenstein, Iceland (PO)
  • 25 Sep 2015 Levodopa/carbidopa extended release is available for licensing in the EU as of September 2015 (www.impaxlabs.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top